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Understanding	 the	 circuits	 that	 promote	 an	 efficient	 resolution	 of	 inflammation	 is	 crucial	 to	
deciphering	 the	molecular	 and	 cellular	 processes	 required	 to	 promote	 tissue	 repair.	Macrophages	
play	 a	 central	 role	 in	 the	 regulation	 of	 inflammation,	 resolution	 and	 repair/regeneration.	 Using	 a	
model	 of	 skeletal	 muscle	 injury	 and	 repair,	 herein	 we	 identified	 Annexin	 A1	 (AnxA1)	 as	 the	
extracellular	trigger	of	macrophage	skewing	towards	a	pro-reparative	phenotype.	Brought	 into	the	
injured	tissue	initially	by	migrated	neutrophils,	and	then	over-expressed	in	infiltrating	macrophages,	
AnxA1	 activated	 FPR2/ALX	 receptors	 and	 the	 downstream	 AMPK	 signalling	 cascade	 leading	 to	
macrophage	 skewing,	dampening	of	 inflammation	and	 regeneration	of	muscle	 fibres.	Mice	 lacking	
AnxA1	 in	 all	 cells	 or	 in	 myeloid	 cells	 only	 displayed	 a	 defect	 in	 this	 reparative	 process.	 In	 vitro	











manner,	 enabling	 the	 restoration	 of	 tissue	 homeostasis	 (1,	 2).	 Indeed,	 chronic	 inflammation	 that	
results	 from	 failure	 of	 resolution	 represents	 a	 major	 contributing	 factor	 to	 a	 multitude	 of	
pathologies,	from	arthritis	to	sepsis	to	dementia	(3,	4)	
	
An	 inflammatory	 reaction	 consists	 of	 the	 co-ordinated	 activity	 of	 numerous	 cells	 and	 soluble	
mediators,	but	a	central	role	is	played	by	the	macrophage.	These	cells,	whether	resident	in	the	tissue	
or	recruited	from	circulating	monocyte	populations,	are	amongst	the	first	responders	to	pathogen-	
or	 damage-associated	 molecular	 patterns,	 initiating	 endothelial	 activation	 and	 neutrophil	
recruitment	 (5).	 Beyond	 their	 roles	 as	 sentinels,	 macrophages	 are	 important	 drivers	 of	 the	
progression	 of	 an	 inflammatory	 response,	 acting	 to	 clear	 pathogens,	 effete	 cells	 and	 debris	 by	
phagocytosis	 (6),	 serving	 as	 antigen	 presenting	 cells	 to	 recruit	 the	 adaptive	 arm	 of	 the	 immune	
response	(7),	and	ultimately	enabling	processes	of	tissue	repair	and	resolution	(8,	9).	That	one	cell	
type	is	able	to	achieve	this	diverse	array	of	functions	is	due	in	large	part	to	its	remarkable	degree	of	




A	 number	 of	 factors	 promoting	 this	 phenotypic	 transformation	 have	 been	 studied	 including	
exposure	 to	 anti-inflammatory	 cytokines	 such	 as	 interleukin	 (IL)-10	 and	 IL-4,	 and	 the	 phagocytic	
removal	of	cell	debris,	although	a	complete	description	of	the	underlying	mechanisms	is	lacking	(11).	
We	and	others	have	identified	a	key	role	for	the	intracellular	signalling	pathway	governed	by	AMP-
activated	 protein	 kinase	 (AMPK)	 (12–14).	 Activation	 of	 this	 pathway	 is	 required	 for	 efficient	
conversion	 of	 pro-	 to	 anti-inflammatory-type	 macrophages,	 and	 inhibition	 of	 such	 a	 response	
significantly	 attenuated	 recovery	 in	 a	 model	 of	 inflammatory	 skeletal	 muscle	 injury	 (13).	 Whilst	
AMPK	is	undoubtedly	important	in	the	phenotypic	conversion	of	macrophages	during	the	course	of	
an	 inflammatory	 reaction,	 the	 nature	 of	 the	 extracellular	 trigger(s)	 for	 its	 stimulation	 remains	
unclear.		
	





















and	Fpr2/3-/-	mice	 (Fig	1A-B,	 Suppl	 Fig	1A-B),	 recovery	of	muscle	mass	 following	administration	of	
cardiotoxin	was	significantly	reduced	in	AnxA1-/-	and	Fpr2/3-/-	mice	than	in	wild-type	animals	(Fig	1B).	
Histological	 analysis	 of	muscles	 28	 days	 post-injury	 revealed	 significantly	 reduced	myofibre	 cross-
sectional	area	(CSA)	and	myonuclei	per	 fibre	(i.e.,	the	result	of	differentiation	and	fusion	of	muscle	
stem	cells)	 in	AnxA1-/-	and	Fpr2/3-/-	animals	 (Fig	1C-E).	These	outcomes	are	suggestive	of	 impaired	
skeletal	muscle	regeneration,	a	notion	confirmed	by	marked	lipid	accumulation	in	AnxA1-/-	mice	(Fig	
1F,	 Suppl	 Fig	 1D).	 Analysis	 of	 immune	 cell	 infiltration	 by	 flow	 cytometry	 revealed	 that	 2	 days	
following	cardiotoxin	administration,	approximately	60%	of	macrophages	expressed	a	pro-resolving,	
anti-inflammatory	phenotype	(CD45+Ly6C/GnegF4/80hi)	in	wild-type	mice,	whilst	AnxA1-/-	and	Fpr2/3-/-	




that	 a	 proportion	 of	 pro-inflammatory	 macrophages	 failed	 to	 convert	 to	 an	 anti-inflammatory	
phenotype	 at	 the	 time	 of	 resolution	 in	 the	 absence	 of	 AnxA1	 or	 Fpr2/3.	 Inactivation	 of	 the	 Fpr1	
receptor,	 another	 member	 of	 the	 Fpr	 family,	 did	 not	 reproduce	 these	 results	 (Suppl	 Fig	 1F-G),	











Fig	 3B-D)	 indicated	 that	 this	 mediator	 was	 primarily	 restricted	 to	 immune	 cells	 until	 day	 2	 post-
lesioning.	Whilst	 F4/80+	murine	macrophages	expressed	AnxA1	at	 all	 time-points	examined	 (Suppl	







mice	 bearing	wild-type	muscle	 but	 AnxA1-/-	 bone	marrow-derived	 leukocytes.	 Therefore,	 CX3CR1-
GFP	mice,	which	harbour	GFP-expressing	monocytes/macrophages	were	irradiated	and	transplanted	
with	 wild-type	 or	 AnxA1-/-	 derived	 bone	 marrow	 cells,	 prior	 to	 injection	 of	 cardiotoxin	 in	 the	 TA	




injury	 revealed	that	animals	 receiving	AnxA1-/-	bone	marrow	cells	displayed	a	significantly	 reduced	
myofibre	CSA	than	animals	receiving	wild-type	bone	marrow	cells	(Fig	2D-E).	Since	more	than	90%	of	
the	macrophages	present	in	the	injured	muscles	originated	from	the	transplanted	marrow	(Suppl	Fig	





pro-inflammatory	 to	 a	 pro-resolving/reparative	 phenotype,	 we	 investigated	 these	 effects	 in	 vitro	
using	human	PBMC-derived	macrophages.	An	M1-like	macrophage	phenotype	was	induced	by	24	h	
incubation	with	bacterial	lipopolysaccharide	(LPS)	and	γ-interferon	(IFNγ),	prior	to	addition	of	human	
recombinant	 ANXA1	 (hrANXA1).	 Following	 hrANXA1	 treatment,	 analysis	 of	 cell	 surface	 markers	
revealed	 a	 significant	 reduction	 in	 expression	 of	 the	M1	marker	 protein	major	 histocompatibility	
complex	 II	 (MHCII)	 (Fig	3A),	accompanied	by	a	significant	 increase	 in	expression	of	 the	M2	marker	




changes	 in	Tgfb1	 expression	were	quantified	 (Fig	3F).	 Together,	 these	 in	 vitro	 data	 support	our	 in	
vivo	 findings,	 providing	 evidence	 that	 ANXA1	 application	 favours	 a	 pro-resolving	 macrophage	
phenotype.		
	
Intriguingly,	 we	 observed	 significant	 FPR2/ALX	 surface	 expression	 both	 in	 unstimulated	 human	
PBMC-derived	macrophages	and	M1-phenotype	cells,	yet	cell	surface	expression	of	the	receptor	was	
lost	 on	 cells	 stimulated	 towards	 an	 M2	 phenotype	 with	 IL-4	 (Suppl	 Fig	 4).	 These	 data	 are	 in	
agreement	 with	 the	 in	 vivo	 observation	 that	 Fpr2/3-/-	 is	 absent	 from	 macrophages	 that	 have	
infiltrated	 the	 injured	muscle	 at	Day	7	 and	beyond,	 that	 is,	when	a	 reparative	 cell	 phenotype	has	
been	 acquired	 (Suppl	 Fig	 2B-C).	 The	 functional	 engagement	 of	 FPR2/ALX	 was	 then	 confirmed	
through	 the	 use	 of	 the	 selective	 antagonist	 WRW4.	 The	 modulatory	 effects	 of	 hrANXA1	 on	 pro-
inflammatory	 PBMC-derived	macrophages	 (i.e.	 reduced	 surface	MHCII	 expression	 and	 augmented	
surface	CD206	expression)	were	lost	in	the	presence	of	WRW4	(Fig.	3G-H).		
	
Together	 these	 experiments	 represent	 a	 clear	 in	 vitro	 counterpart	 to	 the	 effects	 observed	 in	 the	




The	 enzyme	 5'-adenosine	monophosphate-activated	 protein	 kinase,	 AMPK,	 plays	 a	 critical	 role	 in	
macrophage	 phenotype	 skewing	 and	 is	 necessary	 for	 efficient	 regeneration	 after	 skeletal	 muscle	









to	 FPR2/ALX	 was	 confirmed	 through	 analysis	 of	 the	 effects	 of	 the	 antagonist	 WRW4,	 which	
abrogated	hrANXA1-evoked	AMPKα	phosphorylation	in	human	macrophages	(Fig	4E).	The	specificity	








We	 investigated	 the	 relationship	 between	 FPR2/ALX-mediated	 AMPK	 activation	 and	 the	 shift	 in	




mice	 (Fig	 5A).	 Correspondingly,	 hrANXA1	 treatment	 augmented	 the	 proportion	 of	 wild	 type	 cells	
expressing	 the	 anti-inflammatory	markers	 TGFβ1	 (notably	 at	 variance	 from	human	macrophages),	




primary	 PBMC-derived	 macrophages	 with	 three	 distinct	 siRNA	 constructs	 targeting	 the	 AMPKα1	







that	 macrophage	 phenotype	 shifting	 can	 be	 induced	 through	 an	 ANXA1/FPR2/AMPK	 cascade.	 To	
investigate	whether	this	process	underlies	differences	in	recovery	from	cardiotoxin-induced	muscle	
lesions	 seen	 between	 wild-type	 and	 AnxA1-/-	 and	 Fpr2/3-/-	 mice,	 we	 made	 use	 of	 an	 established	
model	of	in	vitro	muscle	repair	(13,	29).		
	
We	 employed	 an	 in	 vitro	model	 of	 adult	myogenesis	 in	which	 conditioned	medium	 from	 primary	
BMDM	 was	 used	 to	 stimulate	 primary	 murine	 myoblasts	 for	 72h,	 quantifying	 the	 proportion	 of	
multinucleated	myotubes	 (Fig	5F).	As	such	 this	 in	vitro	 setting	 recapitulates	 the	processes	of	adult	
myogenesis	 (activation,	 differentiation,	 migration	 and	 fusion	 of	 muscle	 cells)	 that	 occur	 during	









The	 timely	 resolution	 of	 inflammation	 is	 a	 fundamental	 requirement	 for	 restoring	 homeostasis	
following	 infection	or	 damage,	with	 its	 failure	 being	 a	 significant	 contributory	 factor	 to	 numerous	
chronic	inflammatory	pathologies.	Macrophages	are	key	players	in	this	process,	given	their	ability	to	
transition	 from	generally	pro-inflammatory	 to	anti-inflammatory	phenotypes	 (7).	Substantial	effort	
has	gone	into	deciphering	the	complex	signals	underpinning	macrophage	plasticity,	with	numerous	
soluble	mediators	having	been	implicated	(11),	but	the	mechanistic	link	between	these	factors	and	
changes	 in	 phenotype	 remains	 poorly	 understood	 especially	 when	 investigated	 in	 specific	 tissue-
restricted	 settings.	 In	 the	 current	 study,	we	 have	 employed	 a	well-characterised	model	 of	muscle	
injury	 and	 recovery	 (13)	 to	 identify	 the	 ability	 of	myeloid	 cell-derived	ANXA1	 to	 promote	 an	 anti-
inflammatory	macrophage	phenotype,	promoting	resolution	and	tissue	repair.	Moreover,	we	show	





inflammatory	 resolution,	 and	 add	 to	 its	 known	 roles	 in	 regulating	 neutrophil	 apoptosis	 (17),	
efferocytosis	(20,	30),	and	the	recruitment	of	monocytes	to	inflammatory	sites	(18).	Notably,	despite	
muscle	 tissue	 itself	 beginning	 to	 express	 ANXA1	 during	 tissue	 repair,	 as	 noted	 previously	 (31),	
experiments	 with	 chimeric	 mice	 confirmed	 that	 in	 our	 experimental	 settings	 the	most	 important	
source	of	the	protein	to	enable	muscle	repair	remains	the	myeloid	cells	themselves.	Moreover,	while	
previous	 studies	 have	 highlighted	 a	 direct	 plasma	 membrane	 action	 for	 extracellular	 ANXA1	 in	
myoblast	 fusion	 in	 vitro	 (32,	 33)	 our	 experiments	 indicate	 that	 Fpr2/3,	 the	 receptor	 target	 for	
ANXA1,	is	not	expressed	by	stromal	and	parenchymal	cells	in	vivo.	This	suggests	that,	at	least	in	the	
context	of	skeletal	muscle	regeneration	post-cardiotoxin	application,	the	action	of	ANXA1	is	mainly	
mediated	 by	 myeloid	 cells,	 which	 in	 turn	 regulate	 myogenic	 cells.	 While	 our	 studies	 do	 not	
absolutely	 identify	 whether	 neutrophils	 or	 macrophages	 are	 the	 primary	 source	 of	 endogenous	
ANXA1	 within	 the	 injured	 tissue,	 neutrophils	 contain	 substantial	 amounts	 of	 this	 mediator	 (34),	
which	we	have	previously	shown	to	be	a	major	monocyte	chemoattractant	(18),	suggesting	that	the	
protein	-	produced	at	an	early	stage	by	and	released	from	infiltrating	neutrophils	(35)		-	may	act	to	
both	 recruit	 monocytes	 and	 promote	 a	 pro-resolving	 phenotype	 in	 the	 resulting	 macrophages.	
Irrespective	of	the	cell	which	is	the	source	of	ANXA1,	the	dependency	upon	the	presence	of	ANXA1-
expressing	 leukocytes	 for	 efficient	macrophage	phenotypic	 conversion	 is	 another	 example	 of	 how	
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further	weight	to	the	 importance	of	 its	receptor	FPR2/ALX	 in	this	process,	 identifying	 it	as	a	major	
determinant	 for	 induction	of	 a	pro-resolving	macrophage	phenotype	 through	AMPK	activation.	Of	
note,	 macrophage	 FPR2/ALX	 expression	 declined	 during	 the	 course	 of	 the	 response	 to	 muscular	






phenotypes,	 a	 feature	 that	 is	 perhaps	 expected	 given	 the	 importance	 of	 this	 cellular	 process	 to	
promote	 restoration	 of	 homeostasis	 after	 infection	 or	 damage;	 these	 factors	 include	 immune	
complexes,	apoptotic	cells	and	specific	cytokines	(38).	Notably	however,	a	significant	proportion	of	
these	 macrophage-polarising	 mediators	 derive	 from	 the	 adaptive	 arm	 of	 the	 immune	 response,	
particularly	from	TH2	lymphocytes	(11).	Herein,	we	identify	signalling	components	derived	from	the	
innate	 side	 of	 the	 immune	 system	 to	 promote	 resolution.	 Moreover,	 these	 results	 support	 the	
concept	 of	 how	 it	 is	 crucial	 to	 decipher	 mediators	 and	 signal(s)	 operative	 in	 specific	 tissues	 and	
organs	 to	 control	macrophage	polarisation	hence	 to	 regulate	 the	whole	process	of	 resolution	and	
repair.		
	





lymphocytes	 are	 characterised	 by	 high	 levels	 of	 glycolysis,	 akin	 to	 the	 Warburg	 metabolic	 shift	
described	 in	 cancer	 (41),	whereas	 immune	cells	with	an	anti-inflammatory	or	pro-resolving	profile	
tend	to	exhibit	greater	mitochondrial	 respiration	 (13,	42,	43).	The	mechanistic	details	of	how	such	
changes	 in	metabolic	phenotype	relate	to	 immune	function,	and	indeed	whether	these	differences	








AMPK	 is	 involved	 in	different	 cellular	mechanisms	 that	 regulate	 skeletal	muscle	homeostasis	 (47).	
Our	 previous	 findings	 highlighted	 the	 importance	 of	 crosstalk	 between	 AMPK	 and	 the	 mTOR	
signalling	pathway	for	the	control	of	muscle	cell	size	in	the	adaptive	response	of	skeletal	muscle	(48–
51).	Moreover,	we	have	recently	shown	that	AMPKα1,	activated	following	phagocytosis,	is	crucial	for	
macrophage	 skewing	 from	 a	 pro-	 to	 an	 anti-inflammatory	 phenotype	 during	 resolution	 (13),	
demonstrating	 that	 the	CAMKKII/AMPKα1	cascade	within	macrophages	 is	 required	 for	proper	and	
complete	 skeletal	 muscle	 regeneration.	 Anti-inflammatory	 macrophages	 promote	 myogenic	
differentiation	 and	 fusion	 (29,	 52,	 53),	 a	 finding	 of	 importance	 for	 skeletal	 muscle	 regeneration	





to	 a	 pro-resolving	 phenotype,	 linking	 leukocyte-derived	 ANXA1,	 FPR2/ALX	 and	 intracellular	 AMPK	












SM,	 TG,	 GJ,	 JG,	 MT	 &	 RM	 performed	 TA	 lesion	 and	 analysis;	 GJ	 &	 RM	 produced	 and	 analyzed	
chimeric	 mice;	 SM,	 TG	 and	 JETK	 performed	 analysis	 of	 human	 macrophages;	 GJ,	 JG,	 MT	 &	 RM	
performed	analysis	of	AMPKα1	null	mice;	TD	&	RM	performed	murine	macrophages	and	myoblast	










(A)	 Experimental	 set-up.	 Acute	 injury	 was	 induced	 by	 cardiotoxin	 (CTX)	 injection	 in	 the	 Tibialis	
Anterior	(TA)	of	Wild-Type,	AnxA1-/-	and	Fpr2/3-/-	mice.	Muscles	were	analysed	0,	7	and	28	days	after	
injury.	(B)	TA	mass	normalised	to	mouse	body	weight.	(C)	Hematoxylin-eosin	(HE)	staining	of	muscles	
28	days	after	 injury.	White	bar	=	50	μm.	 (D-E)	Myofibre	cross-sectional	area	 (D),	number	of	nuclei	












mice.	 Bone	 marrow	 engraftment	 was	 checked	 on	 a	 blood	 sample	 after	 around	 5	 weeks.	 Then	
animals	were	injured	in	their	Tibialis	Anterior	by	cardiotoxin	(CTX)	injection	and	muscles	analysed	0	
or	 28	 days	 later.	 Engraftment	was	 confirmed	 on	 the	 bone	marrow	 of	 each	 animal	 on	 the	 day	 of	
sacrifice.	(D-E)	HE	staining	(D)	and	myofibre	cross-sectional	area	(E)	of	TA	muscles	28	days	post-CTX	





like	 phenotype,	 prior	 to	 addition	 of	 human	 recombinant	 ANXA1	 (hrANXA1,	 10nM)	 for	 further	 6	
hours.	 (A-B)	Median	 Fluorescent	 Intensity	 (MFI)	 units	measured	 by	 flow	 cytometry	 of	MHCII	 pro-
inflammatory	 (A)	 and	 CD206	 anti-inflammatory	 (B)	 markers.	 Shown	 are	 MFI	 quantification	 (left	
panel)	and	representative	FACS	plots	(right	panel).	(C-F)	RT-qPCR	analysis	of	Tnfa	(C)	and	Nos-2	(D)	
pro-inflammatory	 genes,	 and	 Il-10	 (E)	 and	 Tgfb1	 (F)	 anti-inflammatory	 genes.	 (G-H)	 MFI	 units	 as	










are	 representative	 blots	 (B)	 and	 quantification	 of	 pAMPKα1	 to	 AMPKα1	 (C)	 and	 pACC	 to	 ACC	 (D)	
ratios.	(E)	Representative	western	blot	(top	panel)	and	quantification	(bottom	panel)	of	pAMPKα1	to	
AMPKα1	 ratio	 in	 human	 PBMC-derived	 macrophages	 treated	 by	 hrANXA1	 in	 the	 presence	 or	
absence	 of	 10	µM	WRW4.	 (F)	 Representative	western	 blot	 (top	 panel)	 and	 quantification	 (bottom	





(A-B)	 Primary	 macrophages	 derived	 from	Wild-Type	 or	 AMPKα1-/-	 mice	 were	 treated	 with	 10nM	
hrANXA1	and	 the	percentage	of	 cells	expressing	 the	pro-inflammatory	markers	 iNOS	and	CCL3	 (A)	
and	 the	 anti-inflammatory	 markers	 TGFB1,	 CD163	 and	 CD206	 (B)	 was	 determined	 by	
immunofluorescence.	(C-E)	Human	PBMC-derived	macrophages	were	transfected	by	a	non-targeting	




was	 measured	 by	 immunofluorescence.	 (F)	 Experimental	 set-up.	 (G)	 Representative	 images	 of	
desmin	(red)	and	Hoechst	(blue)	labelling	of	myoblast	cultures.	White	bar	=	50	μm.	(H-I)	Fusion	index	










(D)	 Representative	 images	 of	 Sudan	 black	 staining	 of	 TA	 muscles	 from	 Wild-Type,	 AnxA1-/-	 and	
Fpr2/3-/-	mice	 28	 days	 post-cardiotoxin	 injury.	 (E)	 Representative	 FACS	 plots	 of	 F4/80	 and	 Ly6C/G	









with	 CD45,	 CD64	 and	 Ly6C	 antibodies	 to	 isolate	 Neutrophils	 (Neut)	 and	 Ly6Cpos	 and	 Ly6Cneg	
macrophages	(Mac).	Shown	are	representative	plots	for	day	4	post-CTX	 injury	together	with	purity	
check	 for	 recovered	populations	 (coloured	boxes).	Numbers	 represent	 sorting	purity	 calculated	as	
percentage	of	live	cells.	(B)	CD45neg	cells	were	labelled	with	CD45,	CD31,	Sca-1,	α7-integrin	and	CD34	
antibodies	 to	 isolate	 endothelial	 cells	 (EC),	 FAPs	 (FAP)	 and	 satellite	 cells	 (SAT).	 Shown	 are	




Suppl	 Fig	 3.	 Related	 to	 Figure	 2.	 Immune	 cell	 recruitment	 and	 pattern	 of	 AnxA1	 expression	 in	
cardiotoxin-induced	muscle	injury	and	repair.	
(A)	Anxa1	mRNA	level	measured	by	RT-qPCR	on	sorted	cell	populations	from	Tibialis	Anterior	muscle	
after	 cardiotoxin	 injury.	 (B-D)	 Immunofluorescence	 analysis	 of	 ANXA1	 protein	 in	 Tibialis	 Anterior	




Suppl	 Fig	 4.	Related	 to	 Figure	2.	 Immune	 cell	 recruitment	 and	 Fpr2/3	expression	 in	 cardiotoxin-
induced	muscle	injury	and	repair.	
(A)	Fpr2/3	mRNA	level	measured	by	RT-qPCR	on	sorted	cell	populations	from	Tibialis	Anterior	muscle	
after	cardiotoxin	 injury.	 (B-C)	Quantification	of	F4/80+	ANXA1+	cells	 in	Tibialis	Anterior	 (TA)	muscle	
after	cardiotoxin	(CTX)	 injury.	Representative	 immunofluorescence	analysis	of	Fpr2/3	protein	 in	TA	
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of	macrophages	with	 host	 or	 donor	 origin	 based	 on	 their	 GFP	 expression.	 Shown	 are	 TA	muscles	
between	day	2	and	day	8	post-CTX	injury.	
	
Suppl	 Fig	 6.	 Related	 to	 Figure	 3.	 FPR2/ALX	 expression	 varies	 following	 human	 macrophage	
polarisation.	
Human	 primary	 macrophages	 were	 polarised	 into	 M1	 or	 M2	 macrophages	 with	 IFNg	 and	 IL-4,	
respectively	(A-C)	Flow	cytometry	analysis	of	FPR2/ALX	expression.	Shown	are	representative	FACS	
plots	(A),	percentage	of	cells	expressing	FPR2/ALX	(B)	and	FPR2/ALX	MFI	(C).	(D)	RT-qPCR	analysis	of	




(A)	 Human	 PBMC-derived	 macrophages	 were	 transfected	 by	 a	 non-targeting	 or	 three	 different	










in	 compliance	 with	 European	 legislation	 in	 France.	 Animal	 facilities	 are	 fully	 licensed	 by	 relevant	
national	 authorities	 and	protocols	 have	 been	 validated	 by	 local	 ethical	 committees.	Male	 C57Bl/6	
mice,	male	alx/fpr2/3GFP/GFP	mice	 (referred	 to	 as	 Fpr2/3-/-)	 bearing	 a	 knocked-in	 green	 fluorescent	





purified	essentially	as	described	previously	 (55).	Briefly,	cDNA	for	human	ANXA1	was	 inserted	 into	
the	 expression	 vector	 pQE30Xa	 (Qiagen)	 and	 transfected	 into	 E.coli	 (#SG13009	 pREP4,	 Novagen)	
which	 were	 then	 grown	 in	 Luria-Bertani	 broth	 medium	 supplemented	 with	 ampicillin	 (50	 μg/ml,	
Roche),	kanamycin	(30	μg/ml,	Thermofisher)	and	0.5%	glycerol.	Protein	overexpression	was	initiated	
by	addition	of	5mM	isopropyl	β-D-1-thiogalactopyranoside	(Eurogentec)	and	proteins	were	purified	
by	 IMAC.	 Purity	 and	 homogeneity	 were	 assessed	 by	 SDS-PAGE,	 western	 blotting	 and	 MALDI-
TOF/TOF	 analysis.	 Endotoxin	 was	 determined	 with	 the	 Endosafe-PTS	 (FDA-licensed	 LAL	 cartridge	





Anterior	 (TA)	muscle	of	male	animals,	as	described	previously	 (13).	TA	muscles	were	 injected	with	
cardiotoxin	 (50	 µl	 per	 TA,	 12	 µM);	 1,	 2,	 7,	 14	 or	 28	 days	 post-lesioning	 animals	 were	 killed	 by	
exposure	to	CO2.	TA	were	isolated	and	snap-frozen	in	liquid	nitrogen-cooled	isopentane	for	storage	




Bone	 marrow-derived	 macrophages	 (BMDMs)	 were	 prepared	 from	 adult	 male	 wild-type	
sv129/C57Bl6	 and	 Prkaa1-/-	 mice	 (referred	 to	 as	 AMPKα1-/-	 (28))	 .	 Mice	 were	 killed	 by	 cervical	
dislocation	 under	 isofluorane	 anaesthesia,	 and	marrow	was	 flushed	 from	 tibiae	 and	 femurs.	 Cells	
were	 plated,	 washed	 and	 grown	 for	 6-7	 days	 in	 DMEM	 High	 Glucose	 High	 Pyruvate,	 20%	 heat	
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inactivated	fetal	calf	serum	(ThermoFisher),	30%	L929-cell	conditioned	medium,	1%	Amphotericin	B	




NOS2	 (#ab15323,	 Abcam),	 anti-CCL3	 (#ab32609,	 Abcam),	 anti-TGFβ1	 (#ab64715,	 Abcam),	 anti-
CD163	(#sc-20066,	Santa-Cruz)	and	anti-CD206	(#sc-58987,	Santa-Cruz),	followed	by	incubation	for	1	
hour	at	37°C	with	FITC-	or	Cy3-conjugated	secondary	antibodies	(Jackson	Immunoresearch	Inc).	Cells	
were	 stained	 with	 Hoechst	 (Sigma)	 and	 mounted	 in	 Fluoromount	 (Interchim)	 and	 pictures	 were	













the	 case	of	direct	 treatment	of	MPCs,	 cells	were	directly	 incubated	with	10	nM	of	hrANXA1	 for	3	
days	in	presence	of	2%	heat	inactivated	horse	serum.	Cells	were	then	incubated	with	an	anti-desmin	











min	with	a	dose	of	0.85	Gy/min	 in	an	X-RAD	320	 (Precision	X-Ray).	 Total	bone	marrow	cells	were	
injected	(107	cells	diluted	in	100	μL	of	RPMI-1640	/	50	%	mouse	serum)	into	the	retro-orbital	vein	of	
recipient	 mice.	 After	 transplantation,	 mice	 were	 fed	 with	 ciprofloxacin	 (10	 mg/kg/day)	 in	 the	
drinking	 water	 for	 3-weeks.	 Engraftment	 efficiency	 was	 determined	 on	 peripheral	 blood	 5	 weeks	
after	the	transplantation	and	on	bone	marrow	when	mice	were	sacrificed	by	FACS	analysis.	Briefly,	
red	 cells	 were	 lysed	 with	 ACK	 buffer	 and	 leukocytes	 were	 incubated	 with	 FcR	 Blocking	 Reagent	





Human	 cells	 were	 prepared	 according	 to	 an	 approved	 protocol	 (East	 London	 &	 the	 City	 Local	
Research	 Ethics	 Committee;	 no.	 06/Q605/40;	 P/00/029).	 Peripheral	 blood	 was	 collected	 from	 6	
different	 healthy	 volunteers	 by	 intravenous	 withdrawal	 in	 3.2%	 sodium	 citrate	 solution	 (1:10).	
Peripheral	 blood	mononuclear	 cells	were	 isolated	by	density	 centrifugation	on	 a	Histopaque-1077	
gradient	(Sigma)	according	to	the	manufacturer’s	 instructions,	and	were	plated	 in	RPMI	1640	for	1	





For	histological	analysis,	muscles	were	harvested,	snap	 frozen	 in	 liquid	nitrogen-chilled	 isopentane	
and	kept	at	-80°C	until	use.	Cryosections	(10µm)	were	prepared	for	hematoxylin-eosin	(HE)	or	Sudan	
Black	staining.	Stained	sections	were	scanned	using	an	Axio	Scan.Z1	(Zeiss)	with	a	20x	objective	an	a	
3	CCD	HV-F	2025	CL	 camera	 (Hitachi)	and	Sudan	Black	 labelled	areas	were	quantified	with	 ImageJ	
software.	 Briefly,	 images	were	 converted	 into	 8-bit	 binary	 image	 using	 “Yen”	 threshold	 filter	 and	
black	pixels	were	numerated	and	expressed	as	a	percentage	of	the	total	pixels	in	the	muscle	section.		




or	 Fpr2/3	 (1:100,	 #sc-18191-R,	 SantaCruz).	 Secondary	 antibodies	 were	 Alexa	 Fluor	 488-	 or	 594-
conjugated	 goat	 anti-rabbit	 or	 anti-rat	 IgG	 (1:300;	 Invitrogen).	 Sections	were	 counterstained	with	
DAPI,	 mounted	 and	 examined	 using	 a	 TCS	 SP5	 confocal	 laser	 scanning	 microscope	 (Leica	
	 21	
Microsystems)	fitted	with	405	nm,	488	nm	and	594	nm	lasers,	and	attached	to	a	Leica	DMI6000CS	






from	 regenerating	 muscle	 TA	 using	 magnetic	 beads	 conjugated	 to	 anti-CD45	 antibody	 (Milteny	
Biotec)	and	then	incubated	with	Fc-block	(Milteny	Biotec)	for	30	min	at	4°C.	Finally,	CD45+	cells	were	
stained	with	antibody	against	Ly-6C/G	(#17-5931-82,	eBioscience)	and	against	F4/80	(#12-4801-82,	
eBioscience).	 Percentages	 of	 Ly-6C/GhiF4/80low	 and	 Ly-6C/GnegF4/80hi	 cells	 were	 calculated	 among	




Primary	 human	 PBMC-derived	 macrophages	 were	 transfected	 with	 one	 of	 three	 different	
commercial	 siRNA	 sequences	 designed	 to	 target	 AMPKα1	 or	 an	 Allstars	 negative	 control	 siRNA	
sequence	 using	 Hiperfect	 transfection	 reagent	 according	 to	 the	manufacturer’s	 instructions	 (final	
concentration	2	nM;	all	Qiagen	GmbH,	Hilden,	Germany),	alongside	mock	transfected	cells.	After	48	




ice-cold	 methanol.	 Surface	 FcγR	 were	 blocked	 by	 incubation	 for	 20	 min	 at	 4°C	 with	 IgG	 block	
(ThermoFisher	 Scientific,	 UK)	 then	 incubated	 for	 30	min	 at	 4°C	 with	 a	 rabbit	 polyclonal	 antibody	
raised	against	the	human	AMPKα1	subunit	(1:1,000,	#2795,	Cell	Signalling	Technology),	followed	by	
an	 AF488-conjugated	 goat	 anti-rabbit	 polyclonal	 secondary	 antibody	 (1:500,	 #A-11008,	
ThermoFisher	 Scientific,	 UK)	 staining.	 Cells	were	 analysed	 on	 a	 FACS	 Canto	 II	 flow	 cytometer	 (BD	





anti-MHCII	 (#11-9956-42,	 Thermofisher)	 and	 APC-conjugated	mouse	monoclonal	 anti-CD206	 (#17-
	 22	
2069-42,	Thermofisher)	or	isotype	controls	(all	Thermofisher)	according	to	manufacturer’s	protocols.	










phosphatase	 and	 protease	 inhibitor	 cocktail	 (ThermoFisher	 Scientific,	 UK).	 Samples	 boiled	 in	 6×	
Laemmli	 buffer	 were	 subjected	 to	 standard	 SDS-PAGE	 (10%)	 and	 electrophoretically	 blotted	 onto	
Immobilon-P	 polyvinylidene	 difluoride	 membranes	 (Millipore,	 Watford,	 UK).	 Membranes	 were	
incubated	 with	 antibodies	 raised	 against	 human	 phospho-Ca2+/calmodulin-dependent	 kinase	
(#12716,	Cell	Signalling	Technology),	phospho-AMPKα	(#2531,	Cell	Signalling	Technology),	AMPKα1	
(#2795,	 Cell	 Signalling	 Technology),	 phospho-acetyl-CoA	 carboxylase	 (#3661,	 Cell	 Signalling	
Technology),	acetyl-CoA	carboxylase	(#3662,	Cell	Signalling	Technology,	all	1:1000),	ANXA1	(1:1000,	
#71-3400,	 ThermoFisher	 Scientific,	 UK)	 or	 β-actin	 (1:10,000;	 #A5316,	 Sigma)	 in	 Tris-buffer	 saline	
solution	containing	0.1	%	Tween-20	and	5	%	 (w/v)	non-fat	dry	milk	overnight	at	4	 °C.	Membranes	
were	washed	 for	 30	minutes	with	 Tris-buffer	 saline	 solution	 containing	 0.1	%	 Tween-20,	with	 the	
solution	 being	 changed	 at	 10	 minute	 intervals;	 membranes	 were	 then	 incubated	 with	 secondary	
antibody	(horseradish	peroxidase–conjugated	goat	anti-mouse	1:5000;	ThermoFisher),	for	2	hours	at	
room	temperature.	Proteins	were	then	detected	using	the	enhanced	chemiluminescence	detection	
















For	 Anxa1	 and	 Fpr2/3	 RT-qPCR	 analysis,	 cell	 populations	 were	 FACS-sorted	 from	 mouse	 Tibialis	
Anterior	muscles	as	previously	described	(57)	using	a	FACS	Aria	II	cell	sorter	(BD	Biosciences).	Total	
RNA	 was	 isolated	 using	 NucleoSpin	 RNA	 Plus	 XS	 kit	 (Macherey-Nagel)	 and	 retro-transcribed	 into	
cDNA	 using	 Superscript	 II	 Reverse	 Transcriptase.	 qPCR	 was	 performed	 in	 triplicates	 on	 a	 CFX	
ConnectTM	Real-Time	PCR	Detection	 System	 (Bio-Rad)	using	 LightCycler®	480	 SYBR	Green	 I	Master	
(Roche	 Diagnostics).	 Calculation	 of	 relative	 expression	 was	 determined	 by	 the	 Bio-Rad	 CFX	
ManagerTM	software	and	fold	change	was	normalised	as	Normalised	Relative	Quantity	(or	ΔΔCq)	for	
each	series,	as 𝑁𝑅𝑄 = !∆!"#!!"!#$!∆!"#!!"!#$	where	T	 is	 the	 target	sample,	Cal	 is	 the	calibrator	value	 (i.e.	 the	
mean	of	 all	 sample	 Cqs	 of	 the	 series)	 and	R	 is	 the	 housekeeping	 gene	Cyclophilin	A.	 Sequence	 of	
primers	 used	 were	 as	 follows:	 5’-GCACTCCAGCTTTCTTTGCC-3’	 (Anxa1	 fwd),	 5’-





All	 quantified	 in	 vitro	 data	 are	derived	 from	at	 least	 three	 independent	 donors,	with	 experiments	
performed	 in	 triplicate,	 and	 are	 expressed	 as	 mean	 ±	 SEM.	 Murine	 in	 vivo	 experiments	 were	
performed	with	a	group	size	of	n=6,	sufficient	to	identify	a	20%	effect	size	with	a	power	of	0.8,	and	
are	 expressed	 as	 mean	 ±	 SEM.	 All	 mice	 were	 randomly	 allocated	 to	 groups,	 and	 analysis	 was	







1.	 Perretti	 M,	 Cooper	 D,	 Dalli	 J,	 Norling	 L	 V.	 Immune	 resolution	 mechanisms	 in	 inflammatory	
arthritis.	Nat.	Rev.	Rheumatol.	2017;13(2):87–99.	










7.	 Motwani	 MP,	 Gilroy	 DW.	 Macrophage	 development	 and	 polarization	 in	 chronic	 inflammation.	
Semin.	Immunol.	2015;27(4):257–266.	




10.	 Murray	 PJ	 et	 al.	 Macrophage	 Activation	 and	 Polarization:	 Nomenclature	 and	 Experimental	
Guidelines.	Immunity	2014;41(1):14–20.	




13.	 Mounier	 R	 et	 al.	 AMPKα1	 regulates	 macrophage	 skewing	 at	 the	 time	 of	 resolution	 of	
inflammation	during	skeletal	muscle	regeneration.	Cell	Metab.	2013;18(2):251–64.	
14.	Park	SY	et	al.	 SIRT1/Adenosine	Monophosphate-Activated	Protein	Kinase	α	Signaling	Enhances	
Macrophage	 Polarization	 to	 an	 Anti-inflammatory	 Phenotype	 in	 Rheumatoid	 Arthritis.	 Front.	
Immunol.	2017;8:1135.	
15.	Lim	LHK,	Pervaiz	S.	Annexin	1:	the	new	face	of	an	old	molecule.	FASEB	J.	2007;21(4):968–975.	













22.	 Moraes	 LA	 et	 al.	 Annexin-A1	 enhances	 breast	 cancer	 growth	 and	 migration	 by	 promoting	
alternative	macrophage	polarization	in	the	tumour	microenvironment.	Sci.	Rep.	2017;7(1):17925.	
23.	 Arnold	 L	 et	 al.	 Inflammatory	 monocytes	 recruited	 after	 skeletal	 muscle	 injury	 switch	 into	
antiinflammatory	macrophages	to	support	myogenesis.	J.	Exp.	Med.	2007;204(5):1057–69.	




26.	 d’Albis	 A,	 Couteaux	 R,	 Janmot	 C,	 Roulet	 A,	 Mira	 JC.	 Regeneration	 after	 cardiotoxin	 injury	 of	




28.	 Jørgensen	SB	et	 al.	 Effects	of	α-AMPK	knockout	on	exercise-induced	gene	activation	 in	mouse	
skeletal	muscle.	FASEB	J.	2005;19(9):1146–1148.	









33.	 Bizzarro	 V	 et	 al.	 Role	 of	 Annexin	 A1	 in	 mouse	 myoblast	 cell	 differentiation.	 J.	 Cell.	 Physiol.	
	 26	
2010;224(3):757–765.	
34.	 Francis	 JW,	 Balazovich	 KJ,	 Smolen	 JE,	 Margolis	 DI,	 Boxer	 LA.	 Human	 neutrophil	 annexin	 I	
promotes	 granule	 aggregation	 and	modulates	 Ca(2+)-dependent	membrane	 fusion.	 J.	 Clin.	 Invest.	
1992;90(2):537–44.	
35.	 Damazo	 AS,	 Yona	 S,	 Flower	 RJ,	 Perretti	 M,	 Oliani	 SM.	 Spatial	 and	 temporal	 profiles	 for	 anti-










40.	Pearce	EL,	Pearce	EJ.	Metabolic	pathways	 in	 immune	cell	 activation	and	quiescence.	 Immunity	
2013;38(4):633–43.	
41.	 Rodriguez-Prados	 J-C	 et	 al.	 Substrate	 Fate	 in	 Activated	Macrophages:	 A	 Comparison	 between	
Innate,	Classic,	and	Alternative	Activation.	J.	Immunol.	2010;185(1):605–614.	




44.	 Van	 den	 Bossche	 J,	 O’Neill	 LA,	 Menon	 D.	 Macrophage	 Immunometabolism:	 Where	 Are	 We	
(Going)?	Trends	Immunol.	2017;38(6):395–406.	








49.	 Lantier	 L	 et	 al.	 Coordinated	maintenance	of	muscle	 cell	 size	 control	 by	AMP-activated	protein	
	 27	
kinase.	FASEB	J.	2010;24(9):3555–61.	
50.	 Mounier	 R	 et	 al.	 Antagonistic	 control	 of	 muscle	 cell	 size	 by	 AMPK	 and	 mTORC1.	 Cell	 Cycle	
2011;10(16):2640–6.	
51.	Mounier	 R	 et	 al.	 Important	 role	 for	 AMPKalpha1	 in	 limiting	 skeletal	muscle	 cell	 hypertrophy.	
FASEB	J.	2009;23(7):2264–73.	
52.	 Saclier	M	 et	 al.	 Differentially	 activated	macrophages	 orchestrate	myogenic	 precursor	 cell	 fate	
during	human	skeletal	muscle	regeneration.	Stem	Cells	2013;31(2):384–96.	








57.	 Juban	 G	 et	 al.	 AMPK	 Activation	 Regulates	 LTBP4-Dependent	 TGF-beta1	 Secretion	 by	 Pro-






















































































































































































































































































GFP / AnxA1-/- GFP / WT
D E
Supplementary Figure 5
C
X
3C
R
1
CD64
GFP/WTGFP/GFP
7,6
92,4
95
5
BA C D
M0
M1
M2
2nd only
FPR2/ALX intensity
C
el
l F
re
qu
en
cy
Supplementary Figure 6
β-actin
AMPKα1
Supplementary Figure 7
A B
